Press Release
« Back
TG Therapeutics, Inc. Announces Clinical and Pre-Clinical Poster Presentations for TG-1101 and TGR-1202 at the European Hematology Association (EHA) Meeting in Stockholm, Sweden
Jun 17, 2013
TG-1101 (Ublituximab)
- Poster #325 (June 14): Clinical update entitled "Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies "
- Poster #111 (June 14): Clinical update entitled "Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)"
TGR-1202
- Poster #753 (June 15): Pre-clinical update entitled "TGR-1202: A Novel, PI3K-δ Specific Inhibitor in Multiple Myeloma"
A copy of the posters are available at (http://tgtherapeutics.com/pipeline/publications.cfm). A copy of the abstracts from the EHA meeting can be found at http://www.ehaweb.org/congress-and-events/18th-congress/program/abstract-program/.
ABOUT
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early clinical results that supported our decision to move forward into expansion cohorts will not be reproduced once additional patients are treated with TG-1101; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the
data produced from prior pre-clinical and clinical trials; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the
TGTX - G
CONTACT:Source:Jenna Bosco Director- Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4484 Email: ir@tgtxinc.com
News Provided by Acquire Media